Centessa Pharmaceuticals (CNTA) and some subsidiaries struck a deal for up to $200 million of term loans from Oxford Finance and other lenders, according to a regulatory filing late Monday.
The company received an initial $110 million loan, with additional $90 million available in future tranches, subject to clinical milestones and discretion of the lenders, the filing showed.
The loans will mature in December 2029, according to the filing. Proceeds from the initial loan were used to repay its outstanding debt.
Shares of the company were more than 2% lower in recent trading.
Price: 15.96, Change: -0.39, Percent Change: -2.39
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。